Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women

Ángela María Ruiz-Sternberg, Edson D. Moreira, Jaime A. Restrepo, Eduardo Lazcano-Ponce, Robinson Cabello, Arnaldo Silva, Rosires Andrade, Francisco Revollo, Santos Uscanga, Alejandro Victoria, Ana María Guevara, Joaquín Luna, Manuel Plata, Claudia Nossa Dominguez, Edison Fedrizzi, Eugenio Suarez, Julio C. Reina, Misoo C. Ellison, Erin Moeller, Michael RitterChristine Shields, Miguel Cashat, Gonzalo Perez, Alain Luxembourg

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Background: A 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV) vaccine was developed to expand coverage of the previously developed quadrivalent (HPV6/11/16/18; qHPV) vaccine. Methods: Efficacy, immunogenicity, and safety outcomes were assessed in Latin American participants enrolled in 2 international studies of the 9vHPV vaccine, including a randomized, double-blinded, controlled with qHPV vaccine, efficacy, immunogenicity, and safety study in young women aged 16–26 years, and an immunogenicity and safety study in girls and boys aged 9–15 years. Participants (N=5312) received vaccination at Day 1, Month 2, and Month 6. Gynecological swabs were collected regularly in young women for cytological and HPV DNA testing. Serum was analyzed for HPV antibodies in all participants. Adverse events (AEs) were also monitored in all participants. Results: The 9vHPV vaccine prevented HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical, vulvar, and vaginal dysplasia with 92.3% efficacy (95% confidence interval 54.4, 99.6). Anti-HPV6, 11, 16, and 18 geometric mean titers at Month 7 were similar in the 9vHPV and qHPV vaccination groups. Anti-HPV antibody responses following vaccination were higher among girls and boys than in young women. Most (>99%) 9vHPV vaccine recipients seroconverted for all 9 HPV types at Month 7. Antibody responses to the 9 HPV types persisted over 5 years. The most common AEs were injection-site related, mostly of mild to moderate intensity. Conclusions: The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Latin American young women, girls, and boys. These data support 9vHPV vaccination programs in Latin America, a region with substantial cervical cancer burden.

Original languageEnglish (US)
Pages (from-to)63-74
Number of pages12
JournalPapillomavirus Research
StatePublished - Jun 2018

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Virology


Dive into the research topics of 'Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women'. Together they form a unique fingerprint.

Cite this